A feasibility study to inform the design of a randomised controlled trial to identify the most clinically effective and cost-effective length of Anticoagulation with Low-molecular-weight heparin In the treatment of Cancer-Associated Thrombosis (ALICAT)
Background: Venous thromboembolism is common in cancer patients and requires anticoagulation with low-molecular-weight heparin (LMWH). Current data recommend LMWH for anticoagulation as far as 6 months, yet guidelines recommend LMWH beyond 6 months in patients who have ongoing or active cancer. This...
Main Authors: | Simon I Noble, Annmarie Nelson, David Fitzmaurice, Marie-Jet Bekkers, Jessica Baillie, Stephanie Sivell, Joanna Canham, Joanna D Smith, Angela Casbard, Ander Cohen, David Cohen, Jessica Evans, Kate Fletcher, Miriam Johnson, Anthony Maraveyas, Hayley Prout, Kerenza Hood |
---|---|
Format: | Article |
Language: | English |
Published: |
NIHR Journals Library
2015-10-01
|
Series: | Health Technology Assessment |
Online Access: | https://doi.org/10.3310/hta19830 |
Similar Items
-
ALICAT: a customized approach to item selection process in computerized adaptive testing
by: Victor M. G. Jatobá, et al.
Published: (2020-05-01) -
The ethical decisions UK doctors make regarding advanced cancer patients at the end of life - the perceived (in) appropriateness of anticoagulation for venous thromboembolism: A qualitative study
by: Sheard Laura, et al.
Published: (2012-09-01) -
Symptom management, nutrition and hydration at end-of-life: a qualitative exploration of patients’, carers’ and health professionals’ experiences and further research questions
by: Jessica Baillie, et al.
Published: (2018-04-01) -
Diagnosis and management of people with venous thromboembolism and advanced cancer: how do doctors decide? a qualitative study
by: Johnson Miriam J, et al.
Published: (2012-07-01) -
Heparins of enhanced anticoagulant activity
by: Denton, J.
Published: (1982)